KR20150038486A - 중수소화된 아이브루티닙 - Google Patents
중수소화된 아이브루티닙 Download PDFInfo
- Publication number
- KR20150038486A KR20150038486A KR20157005220A KR20157005220A KR20150038486A KR 20150038486 A KR20150038486 A KR 20150038486A KR 20157005220 A KR20157005220 A KR 20157005220A KR 20157005220 A KR20157005220 A KR 20157005220A KR 20150038486 A KR20150038486 A KR 20150038486A
- Authority
- KR
- South Korea
- Prior art keywords
- deuterium
- compound
- hydrogen
- compounds
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261677307P | 2012-07-30 | 2012-07-30 | |
| US61/677,307 | 2012-07-30 | ||
| PCT/US2013/052721 WO2014022390A1 (en) | 2012-07-30 | 2013-07-30 | Deuterated ibrutinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150038486A true KR20150038486A (ko) | 2015-04-08 |
Family
ID=48917743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20157005220A KR20150038486A (ko) | 2012-07-30 | 2013-07-30 | 중수소화된 아이브루티닙 |
Country Status (13)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015DN00598A (US07585860-20090908-C00083.png) | 2012-07-30 | 2015-06-26 | Concert Pharmaceuticals Inc | |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN103965201A (zh) * | 2014-04-30 | 2014-08-06 | 淮海工学院 | 一种合成依鲁替尼中间体4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶的方法 |
| CN104945404B (zh) * | 2014-06-25 | 2018-09-14 | 广东东阳光药业有限公司 | 一种n-丙烯羰基哌啶衍生物的制备方法 |
| MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| RU2712440C2 (ru) * | 2015-02-12 | 2020-01-29 | Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд | Способ получения ибрутиниба |
| WO2016132383A1 (en) * | 2015-02-18 | 2016-08-25 | Mylan Laboratories Limited | Process for the preparation of ibrutinib |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| WO2016151438A1 (en) * | 2015-03-20 | 2016-09-29 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
| JP7145080B2 (ja) * | 2016-05-04 | 2022-09-30 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化ｊａｋ阻害剤による脱毛障害の処置 |
| JP7118347B2 (ja) | 2017-04-04 | 2022-08-16 | コンビフォス カタリスツ インコーポレイテッド | 重水素化（ｓ）２－（４－（ピペリジン－３－イル）フェニル）－２ｈ－インダゾール－７－カルボキサミド |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| CN109988175A (zh) * | 2019-04-28 | 2019-07-09 | 梯尔希（南京）药物研发有限公司 | 一种依鲁替尼-d5的制备方法 |
| CN112876484B (zh) * | 2020-08-31 | 2022-06-28 | 绍兴舜邦医药科技有限公司 | 一种氘代依鲁替尼的制备方法 |
| CN112125913A (zh) * | 2020-10-29 | 2020-12-25 | 瑞阳制药股份有限公司 | 高纯度伊布替尼的合成方法 |
| WO2023284765A1 (zh) * | 2021-07-16 | 2023-01-19 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0751926B1 (en) | 1994-03-25 | 2007-09-12 | Isotechnika,Inc. | Enhancement of the efficacy of drugs by deuteration |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| EP1104760B1 (en) | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| DE10155018A1 (de) * | 2001-11-07 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| CA2661404A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| EP2081435B1 (en) * | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US9212285B2 (en) | 2012-02-08 | 2015-12-15 | Council Of Scientific & Industrial Research | Electronically conducting carbon and carbon-based material by pyrolysis of dead leaves and other similar natural waste |
| IN2015DN00598A (US07585860-20090908-C00083.png) * | 2012-07-30 | 2015-06-26 | Concert Pharmaceuticals Inc |
-
2013
- 2013-07-30 IN IN598DEN2015 patent/IN2015DN00598A/en unknown
- 2013-07-30 JP JP2015525512A patent/JP6261580B2/ja not_active Expired - Fee Related
- 2013-07-30 US US14/418,831 patent/US9422295B2/en active Active
- 2013-07-30 WO PCT/US2013/052721 patent/WO2014022390A1/en active Application Filing
- 2013-07-30 AU AU2013296627A patent/AU2013296627C9/en not_active Ceased
- 2013-07-30 MX MX2015001246A patent/MX2015001246A/es unknown
- 2013-07-30 EA EA201590296A patent/EA201590296A1/ru unknown
- 2013-07-30 KR KR20157005220A patent/KR20150038486A/ko not_active Application Discontinuation
- 2013-07-30 ES ES13745554.9T patent/ES2682043T3/es active Active
- 2013-07-30 EP EP13745554.9A patent/EP2882751B1/en active Active
- 2013-07-30 CN CN201380040337.9A patent/CN104507946A/zh active Pending
- 2013-07-30 BR BR112015001839A patent/BR112015001839A2/pt not_active IP Right Cessation
- 2013-07-30 CA CA2879400A patent/CA2879400A1/en not_active Abandoned
-
2016
- 2016-07-27 US US15/220,642 patent/US9777009B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20170015670A1 (en) | 2017-01-19 |
| AU2013296627A1 (en) | 2015-02-05 |
| JP6261580B2 (ja) | 2018-01-17 |
| AU2013296627C9 (en) | 2018-03-22 |
| EA201590296A1 (ru) | 2015-07-30 |
| CN104507946A (zh) | 2015-04-08 |
| ES2682043T3 (es) | 2018-09-18 |
| AU2013296627C1 (en) | 2016-12-15 |
| US9777009B2 (en) | 2017-10-03 |
| AU2013296627B2 (en) | 2016-07-14 |
| CA2879400A1 (en) | 2014-02-06 |
| JP2015528020A (ja) | 2015-09-24 |
| MX2015001246A (es) | 2015-04-10 |
| WO2014022390A1 (en) | 2014-02-06 |
| EP2882751A1 (en) | 2015-06-17 |
| US20150210699A1 (en) | 2015-07-30 |
| US9422295B2 (en) | 2016-08-23 |
| BR112015001839A2 (pt) | 2017-07-04 |
| EP2882751B1 (en) | 2018-06-27 |
| IN2015DN00598A (US07585860-20090908-C00083.png) | 2015-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9777009B2 (en) | Deuterated ibrutinib | |
| US10842792B2 (en) | Deuterated baricitinib | |
| AU2014235462B2 (en) | Deuterated palbociclib | |
| EP2872159A2 (en) | Deuterated carfilzomib | |
| JP2016505015A (ja) | 重水素化モメロチニブ（ｍｏｍｅｌｏｔｉｎｉｂ） | |
| JP2012531419A (ja) | Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体 | |
| US8557815B2 (en) | Substituted triazolophthalazine derivatives | |
| WO2015031741A1 (en) | Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor | |
| WO2012129381A1 (en) | Deuterated preladenant | |
| WO2014081816A1 (en) | Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds | |
| KR20150071493A (ko) | 룩소리티닙의 중수소화된 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| WITB | Written withdrawal of application |